C88.90 — Malignant immunoproliferative disease, unspecified not having achieved remission
C88.90 is a billable, specific ICD-10-CM code for malignant immunoproliferative disease, unspecified not having achieved remission. It is valid for submission on a claim.
Inclusion terms
Alternative wordings a physician may use in the chart for this same code.
- Immunoproliferative disease NOS
- Immunoproliferative disease NOS not having achieved remission
- Immunoproliferative disease NOS with failed remission
- Malignant immunoproliferative disease, unspecified NOS
- Malignant immunoproliferative disease, unspecified with failed remission
Risk adjustment
C88.90 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 21 Lymphoma and Other Cancers0.671 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.
Medicare coverage
C88.90 is named in 38 Medicare coverage policies — 38 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.
- A52479Oral Anticancer Drugs - Policy Article
- A52479Oral Anticancer Drugs - Policy Article
- A52479Oral Anticancer Drugs - Policy Article
- A52479Oral Anticancer Drugs - Policy Article
Code history
What changed, and when. Derived by diffing consecutive CMS release files — which matters when you are defending a code assigned under an earlier edition.
- addedFY2024-FY2026
Malignant immunoproliferative disease, unspecified not having achieved remission
Related codes at this level
Codes that share C88.9. If C88.90 is not quite right, the correct code is usually one of these.
Questions about C88.90
- Is C88.90 a billable ICD-10-CM code?
- Yes. C88.90 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
- Where does C88.90 sit in the tabular list?
- Neoplasms (C00-D49), in the block Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96).